Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.37 |
| ▸ | FPR2 | P25090 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | HTR2B | P41595 | 2/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.33 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13586463 | 0.93 | CNR2 (0.37) | CNR2FPR2HTR2AHTR2CHTR2B | |
| SCHEMBL13586130 | 0.92 | FPR2 (0.36) | CNR2FPR2HTR2AHTR2CHTR2B | |
| SCHEMBL12821156 | 0.91 | FPR2 (0.38) | CNR2FPR2HTR2AHTR2CHTR2B | |
| SCHEMBL13586359 | 0.89 | CNR2 (0.39) | CNR2FPR2HTR2AHTR2CHTR2B | |
| SCHEMBL12822967 | 0.89 | CNR2 (0.39) | CNR2FPR2HTR2AHTR2CHTR2B | |
| SCHEMBL12907045 | 0.88 | CNR2 (0.35) | CNR2FPR2HTR2AHTR2CHTR2B | |
| SCHEMBL12716952 | 0.88 | FPR2 (0.36) | CNR2FPR2HTR2AHTR2CHTR2B | |
| SCHEMBL12821158 | 0.88 | FPR2 (0.34) | CNR2FPR2HTR2AHTR2CHTR2B | |
| SCHEMBL12735836 | 0.87 | KDM1A (0.45) | CNR2FPR2HTR2AHTR2CHTR2B | |
| SCHEMBL13586107 | 0.87 | FPR2 (0.33) | CNR2FPR2HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
| WO-2009150966-A1 | TETRACYCLIC LIQUID CRYSTALLINE COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | チッソ株式会社 (JP) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | CNR2 686/4885FPR2 589/4885HTR2A 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.